Pertuzumab filed for breast cancer in Japan
This article was originally published in Scrip
Executive Summary
Roche's subsidiary Chugai has made an approval filing in Japan for Genentech/Roche's HER-dimerisation inhibitor pertuzumab, for the treatment of HER2-positive metastatic or recurrent breast cancer.